Literature DB >> 15900597

Etiologic factors associated with p53 immunostaining in cutaneousmalignant melanoma.

Mark P Purdue1, Lynn From, Harriette J Kahn, Bruce K Armstrong, Anne Kricker, Richard P Gallagher, John R McLaughlin, Neil S Klar, Loraine D Marrett.   

Abstract

Findings from a case-control study of cutaneous malignant melanoma (CMM) in Queensland, Australia, suggest that melanomas exhibiting p53 immunostaining possess different risk factors from those of other melanomas. To further explore this hypothesis, a case-only analysis of risk factors for p53 immunostaining with anti-p53 MAb DO-7 was undertaken in 523 people diagnosed with CMM in Canada and Australia. Phenotypic factors and past sun exposure were measured using a self-administered questionnaire and telephone interview. The presence of strong p53 staining (>10% of cell nuclei positively stained vs. <1% staining) was positively associated with some indicators of high cumulative sun exposure: lentigo maligna melanoma subtype (OR = 3.2 vs. superficial spreading subtype), melanoma location on the head and neck (OR = 2.8 vs. back), histopathologic evidence of solar elastosis (OR = 2.1) and previous diagnosis of nonmelanoma skin cancer (OR = 2.4). Strong staining was negatively associated with high nevus density on the back (OR = 0.2 for >25 nevi vs. 0-3 nevi) and histologic evidence of a coexisting nevus (OR = 0.3). Other factors associated with strong p53 immunostaining include greater Breslow thickness (OR = 7.4 for >4.00 vs. <0.76 mm), male sex (OR = 2.2) and dense freckling (OR = 6.6 vs. few freckles). Of these, thickness, male sex, dense freckling, low nevus density on the back, histologic subtype and history of nonmelanoma skin cancer appeared to be independently associated with strong p53 staining. Our findings are consistent with the Queensland study in suggesting that variables indicating high accumulated sun exposure are positively associated with p53 staining and that an increased number of nevi is positively associated with its absence; they may reflect etiologic and pathogenetic heterogeneity in melanoma. (c) 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15900597     DOI: 10.1002/ijc.21196

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  8 in total

1.  Biologic markers of sun exposure and melanoma risk in women: pooled case-control analysis.

Authors:  Catherine M Olsen; Michael S Zens; Adele C Green; Therese A Stukel; C D'Arcy J Holman; Thomas Mack; J Mark Elwood; Elizabeth A Holly; Carlotta Sacerdote; Richard Gallagher; Anthony J Swerdlow; Bruce K Armstrong; Stefano Rosso; Connie Kirkpatrick; Roberto Zanetti; Julia Newton Bishop; Veronique Bataille; Yu-Mei Chang; Rona Mackie; Anne Østerlind; Marianne Berwick; Margaret R Karagas; David C Whiteman
Journal:  Int J Cancer       Date:  2010-11-16       Impact factor: 7.396

2.  Melanoma in Situ Treated with Topical Imiquimod for Management of Persistently Positive Margins: A Review of Treatment Methods.

Authors:  Qing Fan; Stephanie Cohen; Becky John; Adam I Riker
Journal:  Ochsner J       Date:  2015

3.  Divergent cancer pathways for early-onset and late-onset cutaneous malignant melanoma.

Authors:  William F Anderson; Ruth M Pfeiffer; Margaret A Tucker; Philip S Rosenberg
Journal:  Cancer       Date:  2009-09-15       Impact factor: 6.860

4.  Mechanism of UV-related carcinogenesis and its contribution to nevi/melanoma.

Authors:  Brozyna Anna; Zbytek Blazej; Granese Jacqueline; Carlson J Andrew; Ross Jeffrey; Slominski Andrzej
Journal:  Expert Rev Dermatol       Date:  2007

5.  Nevus density and melanoma risk in women: a pooled analysis to test the divergent pathway hypothesis.

Authors:  Catherine M Olsen; Michael S Zens; Therese A Stukel; Carlotta Sacerdote; Yu-Mei Chang; Bruce K Armstrong; Veronique Bataille; Marianne Berwick; J Mark Elwood; Elizabeth A Holly; Connie Kirkpatrick; Thomas Mack; Julia Newton Bishop; Anne Østerlind; Anthony J Swerdlow; Roberto Zanetti; Adèle C Green; Margaret R Karagas; David C Whiteman
Journal:  Int J Cancer       Date:  2009-02-15       Impact factor: 7.396

Review 6.  Diagnosis and management of lentigo maligna: a review.

Authors:  Julia M Kasprzak; Yaohui G Xu
Journal:  Drugs Context       Date:  2015-05-29

7.  In vitro evidence for senescent multinucleated melanocytes as a source for tumor-initiating cells.

Authors:  C Leikam; A L Hufnagel; C Otto; D J Murphy; B Mühling; S Kneitz; I Nanda; M Schmid; T U Wagner; S Haferkamp; E-B Bröcker; M Schartl; S Meierjohann
Journal:  Cell Death Dis       Date:  2015-04-02       Impact factor: 8.469

8.  Cutaneous melanoma primary site is linked to nevus density.

Authors:  Alejandro Martin-Gorgojo; Marta Llinares; Amaya Virós; Celia Requena; Zaida Garcia-Casado; Víctor Traves; Rajiv Kumar; Eduardo Nagore
Journal:  Oncotarget       Date:  2017-10-24
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.